Head-To-Head Analysis: BioXcel Therapeutics (NASDAQ:BTAI) and Kazia Therapeutics (NASDAQ:KZIA)

BioXcel Therapeutics (NASDAQ:BTAI) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares BioXcel Therapeutics and Kazia Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$1.38 million	69.24	-$179.05 million	($6.15)	-0.42
Kazia Therapeutics	$20,000.00	290.05	-$13.78 million	N/A	N/A

Kazia Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics.

Institutional and Insider Ownership

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are owned by institutional investors. 35.8% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Kazia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for BioXcel Therapeutics and Kazia Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	0	4	3	0	2.43
Kazia Therapeutics	0	0	0	0	N/A

BioXcel Therapeutics currently has a consensus target price of $16.71, suggesting a potential upside of 547.84%. Given BioXcel Therapeutics’ higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Kazia Therapeutics.

Risk & Volatility

BioXcel Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.

Profitability

This table compares BioXcel Therapeutics and Kazia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-12,974.86%	-890.63%	-144.88%
Kazia Therapeutics	N/A	N/A	N/A

Summary

Kazia Therapeutics beats BioXcel Therapeutics on 7 of the 11 factors compared between the two stocks.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.